Third Quarter 2024 Earnings Teleconference 1 October 29, 2024 Introduction Francesca DeMartino Chief Investor Relations Officer, Senior Vice President Third Quarter 2024 Earnings 2 Forward-Looking Statements and Non-GAAP Financial Information • Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-loo ...

Pfizer, Inc. (NYSE:PFE) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer & SVP Albert Bourla - Chairman & CEO Dave Denton - CFO Mikael Dolsten - Chief Scientific Officer and President of Research & Development Chris Boshoff - EVP & Chief Oncology Officer Alexandre de Germay - EVP & Chief International Commercial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Kripa Devarakonda - Truist Umer Raffat - ...

On October 29, 2024, Pfizer (NYSE: PFE ) reported financial results for the third quarter of 2024 , which exceeded Wall Street analysts' expectations and also pleased me with the progress made in recent months. With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceuti ...

Key TakeawaysPfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.However, shares declined as the results may have put a damper on possible changes to the company demanded by activist investor Starboard Value.CEO Albert Bourla expressed confidence in the way Pfizer is executing its strategy. Shares of Pfizer (PFE) fell Tuesday as a strong earnings report is seen as likely to limit activist investor Starboard Value from driving major changes a ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Pfizer (PFE) reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per share in the year-ago quarter. Revenues came in at $17.7 billion, up 31% from the year-ago quarter on a reported basis, reflecting an operational increase of 32% and a negative currency impact of 1%. Total revenues significantly beat the Zacks Consensus Estimate of $15.19 billion. Higher sales of Pfizer's ke ...

Pfizer (PFE) reported $17.7 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 33.8%. EPS of $1.06 for the same period compares to -$0.17 a year ago.The reported revenue represents a surprise of +16.53% over the Zacks Consensus Estimate of $15.19 billion. With the consensus EPS estimate being $0.64, the EPS surprise was +65.62%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stree ...

Pfizer (PFE) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 65.62%. A quarter ago, it was expected that this drugmaker would post earnings of $0.45 per share when it actually produced earnings of $0.60, delivering a surprise of 33.33%.Over the last four quarters, the company has surpasse ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Exhibit 99 Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance ▪ Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio (1) (2) ▪ Raises Full-Year 2024 Revenue Guidance to a Range of $61.0 to $64.0 Billion and Raises Adjusted Diluted EPS Guidance to a Range of $2.75 to $2.95 ▪ Third-Quarter 2024 Revenues of $17.7 Billion, Representing 32% Year-over-Year Operational Growth – Excluding Contributions from Paxlovid a ...